Synthical
Your space
Profile
Activity
Favorites
Folders
Feeds
All articles
Claim page
D. S. Khoury
Follow
Activity
Upvotes
Folders
Articles
17
Predicting COVID-19 booster immunogenicity against future SARS-CoV-2 variants and the benefits of vaccine updates
27 September 2024 by
Deborah Cromer
and
others
at
University of New South Wales
Infectious Diseases
Predicting vaccine effectiveness in Mpox
8 May 2024 by
M. Berry
and
others
Infectious Diseases
Viral clearance as a surrogate of clinical efficacy for COVID-19 therapies in outpatients: A systematic review and meta-analysis
4 April 2024 by
K. Elias
and
others
Infectious Diseases
Determinants of passive antibody effectiveness in SARS-CoV-2 infection
1 November 2023 by
Eva Stadler
and
others
Infectious Diseases
Monoclonal antibody levels and protection from COVID-19
28 July 2023 by
Eva Stadler
and
others
Infectious Diseases
Estimating long-term vaccine effectiveness against SARS-CoV-2 variants: a model-based approach
19 July 2023 by
A. Hogan
and
others
Epidemiology
Systemic host inflammation induces stage-specific transcriptomic modification and slower maturation in malaria parasites
14 July 2023 by
L. I. M. Lansink
and
others
Microbiology
Predicting the efficacy of variant-modified COVID-19 vaccine boosters
2 March 2023 by
D. Khoury
and
others
Infectious Diseases
A role for super-spreaders in carrying malaria parasites across the months-long dry season
3 February 2023 by
Eva Stadler
and
others
Infectious Diseases
Risk of Plasmodium vivax recurrences follows a 30-70 rule and indicates relapse heterogeneity in the population
19 December 2022 by
Eva Stadler
and
others
Infectious Diseases
SARS-CoV-2 Omicron: reduction of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern
30 May 2022 by
Anay Aggarwal
and
others
Infectious Diseases
Dynamics of immune recall following SARS-CoV-2 vaccination or breakthrough infection
27 May 2022 by
M. Koutsakos
and
others
Infectious Diseases
Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine
8 April 2022 by
Rishi Raj Goel
and
others
at
University of Pennsylvania
Immunology
Relating in vitro neutralisation level and protection in the CVnCoV (CUREVAC) trial.
28 January 2022 by
Deborah Cromer
and
others
Infectious Diseases
SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection
23 December 2021 by
S. Cele
and
others
Infectious Diseases
SARS-CoV-2 variants: levels of neutralisation required for protective immunity
15 November 2021 by
Deborah Cromer
and
others
Infectious Diseases
What level of neutralising antibody protects from COVID-19? .
17 May 2021 by
D. Khoury
and
others
Infectious Diseases
Evolution of immunity to SARS-CoV-2
19 February 2021 by
A. Wheatley
and
others
at
University of Melbourne
Infectious Diseases
This is an AI-generated summary
Key points
Topics
Infectious Diseases
Epidemiology
Microbiology
Immunology